Q-omics provides the consensus-scored ZNF826P profile across patient tissues and cancer cell-line models. ZNF826P expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF826P is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, ZNF826P RNA expression shows 16,927 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, THCA, and THYM as cancer lineages where ZNF826P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF826P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF826P survival associations across molecular data types. ZNF826P RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF826P RNA expression–survival associations across cancer types. High ZNF826P expression shows favorable associations in KIRC, UVM, HNSC, MESO, KIRP and OV. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF826P RNA expression.
This table summarizes ZNF826P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF826P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF826P shows lower tumor expression in THCA, KICH, COAD and BRCA and higher tumor expression in KIRC and LIHC. The THCA box plot shows higher ZNF826P RNA expression in normal versus tumor tissue (log2 FC = −1.799, t-test p < 0.001).
This table shows molecular features associated with ZNF826P in patient tissues and cancer cell lines. In patient samples, ZNF826P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
